ADXS News and Press, Advaxis From 01/25/21

Clinical-stage biotech Advaxis ([[ADXS]] +1.2%) highlighted important clinical and biomarker data from the ongoing Phase 1/2 study of ADXS-503 in Nonsmall-cell lung carcinoma ((NSCLC)) during 2020, and provides full-year 2020 results.The company also talked up its clinical...

Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors SITC presentation from ongoing ADXS-503 Phase 1/2 clinical trial demonstrated disease control rate of 67% and overall response rate ...

Advaxis ([[ADXS]] +15.2%) received the first milestone payment related to its licensing agreement for ADXS31-164, now known as OST-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans.Under the agreement, Advaxis will receive additional clinical, regulatory, an...

PRINCETON, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has received the first milestone payment related to its li...

PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it received a positive determination from the Nasdaq Stock Market granting...

How Will These Penny Stocks Perform in December 2020? With November behind us at this point, December is a new month ripe with potential for penny stocks . While not all penny stocks hold high value, with careful research, we can find the ones that are. One of the best pieces of...

Did These Robinhood Penny Stocks Slip By This Month? Whether you’re trading penny stocks on Robinhood , Webull, TDAmeritrade, ETrade or others, everyone’s got one goal in mind. That goal is making money with these cheap stocks. Robinhood and Webull are usually separate...

PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offerin...

Advaxis (ADXS) prices an underwritten public offering of ~26.7M shares of common stock and warrants to purchase up to ~13.3M shares of common stock.The shares of common stock and warrants are being sold at a price of $0.30/share and warrants at $0.35/share.Underwriters' over-allotment is...

PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offerin...